Physiological changes occurring perinatally and in the first month of life can affect the answer to a pharmacological treatment
and the individual response to a drug in terms of efficacy and toxicity is highly variable in the neonatal population. Among potential
causes for such variability, differences in drug metabolism may have a great impact.
This article aims to review qualitative and quantitative differences in drug metabolizing enzymes in neonates, since both phase I and
phase II metabolic pathways are immature at birth and subject to maturational changes in the first period of extrauterine life.
Moreover, clinical implications will be discussed.
Keywords: Newborns, drugs, enzymes, Drug Metabolizing Enzymes, Perinatal, Neonatal Period, toxicity, phase II, CYP2C, CYP3A5, Sulfation
open access plus
Rights & PermissionsPrintExport